<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500602</url>
  </required_header>
  <id_info>
    <org_study_id>SPLE-001-14F</org_study_id>
    <secondary_id>CX001288</secondary_id>
    <nct_id>NCT02500602</nct_id>
    <nct_alias>NCT02492334</nct_alias>
  </id_info>
  <brief_title>CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders</brief_title>
  <acronym>Doxazosin</acronym>
  <official_title>CAP - Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will examine the efficacy of doxazosin in the treatment of PTSD and&#xD;
      alcohol use disorder or substance use disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to sustained military conflicts in Afghanistan and Iraq over the past decade, there are&#xD;
      an increasing number of U.S. military personnel and Veterans returning home with&#xD;
      posttraumatic stress disorder (PTSD) and comorbid alcohol use disorders (AUD) and substance&#xD;
      use disorders (SUD). If left untreated, Veterans with co-occurring PTSD and substance use&#xD;
      disorders are at increased risk for developing other mental health problems (e.g.,&#xD;
      depression, anxiety), suicidal ideation and attempts, physical health problems, reduced&#xD;
      resiliency and military readiness, employment problems, violence, and family/relationship&#xD;
      impairment. While mental health services are in place for U.S. service members, substantial&#xD;
      gaps in the treatment of co-occurring PTSD and SUD exist and there is little scientific&#xD;
      evidence available to guide the provision of care. As part of the Consortium to Alleviate&#xD;
      PTSD (CAP), the proposed study directly addresses this critical knowledge gap by testing the&#xD;
      efficacy of doxazosin, a long-acting and selective alpha-1 adrenergic antagonist, as compared&#xD;
      to placebo in reducing PTSD and AUD/SUD severity among U.S. military personnel. The&#xD;
      medication to be investigated (doxazosin) represents a novel treatment approach for PTSD and&#xD;
      AUD/SUD. While prazosin, also an alpha-1 adrenergic antagonist, has been shown to improve&#xD;
      sleep and nightmares in military personnel with PTSD and may help reduce substance use&#xD;
      severity, it has a short half-life of 2-3 hours and requires multiple doses each day, which&#xD;
      is a significant limitation. In several pilot studies, doxazosin has shown promise in&#xD;
      significantly reducing symptoms of PTSD and AUD/SUD and, in contrast to prazosin, it requires&#xD;
      once per day dosing which confers a significant advantage in terms of translating positive&#xD;
      findings into routine clinical practice. In this Stage II study, the investigators will (1)&#xD;
      employ a two-arm randomized, double-blind, between-groups experimental design that will&#xD;
      consist of 12 weeks of treatment with doxazosin or placebo medication; (2) use standardized,&#xD;
      repeated dependent measures to rigorously assess PTSD symptomatology and AUD/SUD severity;&#xD;
      (3) measure impairment in associated mental and behavioral health problems (e.g., depression,&#xD;
      anxiety, sleep, risky behaviors, family/social functioning); and (4) use functional magnetic&#xD;
      resonance imaging (fMRI) to investigate the underlying pathophysiology of comorbid PTSD/AUD&#xD;
      and identify prognostic indicators of treatment outcome. To achieve these aims, the&#xD;
      investigators have assembled a multidisciplinary team of investigators with&#xD;
      nationally-recognized expertise in combat-related PTSD, substance use disorders and&#xD;
      neuroimaging who have successfully collaborated in the past and are uniquely qualified to&#xD;
      implement this type of investigation. The investigators represent a collaboration of faculty&#xD;
      at the Ralph H. Johnson Veterans Affairs (VA) Medical Center and the Medical University of&#xD;
      South Carolina (MUSC) in Charleston, SC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">December 16, 2019</completion_date>
  <primary_completion_date type="Actual">December 16, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale</measure>
    <time_frame>12 Weeks</time_frame>
    <description>The primary PTSD outcome measure was the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5; Weathers et al., 2013). The CAPS-5 is a semi-structured interview that measures the DSM-5 symptoms of PTSD and requires the presence of at least one intrusion symptom, one avoidance symptom, two cognition and mood symptoms, and two arousal symptoms for a period of 1 month or more to reach diagnostic threshold. There are 20 symptom items and responses that are rated on a 5-point scale ranging from 0 (absent) to 4 (extreme/incapacitating), with a total PTSD symptom severity score of the sum of the 20 symptom items ranging from 0-80, and lower scores indicating better outcomes (or less severe PTSD symptomology). The CAPS-5 was assessed at end of treatment (week 12).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PTSD Checklist (PCL-5)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>The secondary PTSD outcome measure was the PTSD Checklist-5 (PCL-5; Weathers et al., 2013b). The PCL-5 is 20-item self-report measure that assesses the DSM-5 symptoms of PTSD using a severity rating Likert scale ranging from 0 to 4 that indicates the degree of distress across symptoms (0 = not at all to 4 = extremely). The overall score range is 0-80 (and combines the score for all 20 symptoms), with lower scores representing better outcomes (less severe PTSD symptomology). The PCL-5 was assessed at end of treatment (week 12).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Line Follow Back (TLFB)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>The TLFB obtains retrospective self-report of substance use by using a calendar and memory prompts to stimulate recall (Sobell &amp; Sobell, 1992). Quantity and frequency assessments are made using this instrument (e.g., total number of standard drink units, percent of days using) as well as abstinence (yes/no). TLFB yields consistently high test-retest correlations and correlates well with other self-reports and collateral reports (Sobell et al., 2003). The TLFB assesses frequency and amount of substance use over a pre-determined timeframe. TLFB data were collected throughout the trial, and the values reported here represent the TLFB data at end of treatment (week 12).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <condition>Alcohol Use Disorders</condition>
  <arm_group>
    <arm_group_label>Doxazosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomly assigned to receive doxazosin (target dose of 16 mg/day). Doxazosin will be initiated at 1 mg/day for the first week, 2mg/day for the second week, 4mg/day for the third week, 8mg/day for the fourth week, and then increase to 16 mg/day for the remaining eight weeks (as tolerated). Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomly assigned to placebo. Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxazosin</intervention_name>
    <description>active medication</description>
    <arm_group_label>Doxazosin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo pill</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female; any race or ethnicity.&#xD;
&#xD;
          2. Served in U.S. Military - any branch or operation.&#xD;
&#xD;
          3. Subjects must be able to comprehend English.&#xD;
&#xD;
          4. Meet criteria for current (i.e., last 6 months) Substance Use Disorder (SUD) using a&#xD;
             modified version of the MINI 7.0 (i.e., must meet DSM-5 criteria for SUD in the past 6&#xD;
             months instead of 12 months).&#xD;
&#xD;
          5. Meet DSM-5 criteria for current (i.e., last month) PTSD.&#xD;
&#xD;
          6. Subjects taking psychotropic medications will be required to be maintained on a stable&#xD;
             dose for at least four weeks before treatment initiation. This is because initiation&#xD;
             or change of medications during the course of the trial may interfere with&#xD;
             interpretation of results.&#xD;
&#xD;
          7. Must consent to random assignment to doxazosin or placebo.&#xD;
&#xD;
          8. Must consent to complete all treatment and follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects meeting DSM-5 criteria for current bipolar affective disorders, as the study&#xD;
             protocol may be therapeutically insufficient.&#xD;
&#xD;
          2. Subjects experiencing significant withdrawal symptoms, as evidence by a score of 10 or&#xD;
             above on the Clinical Institute Withdrawal Assessment of Alcohol (CIWA). These subject&#xD;
             will be referred for clinical detoxification and may be re-assessed for study&#xD;
             eligibility after medically supervised detoxification has been completed.&#xD;
&#xD;
          3. Individuals considered an immediate suicide risk or who are likely to require&#xD;
             hospitalization during the course of the study.&#xD;
&#xD;
          4. Previous treatment with doxazosin.&#xD;
&#xD;
          5. Subjects on maintenance anxiolytic, antidepressant, or mood stabilizing medications&#xD;
             which have been initiated during the past four weeks. If it is determined, based on&#xD;
             clinical criteria, that a subject needs to be started on maintenance medications for&#xD;
             anxiety, mood or psychotic symptoms during the course of the study, they may be&#xD;
             discontinued from the treatment trial.&#xD;
&#xD;
          6. Women who are pregnant, nursing or not practicing an effective form of birth control.&#xD;
&#xD;
          7. Individuals with a history of or current medical illness including unstable angina,&#xD;
             myocardial infarction, congestive heart failure or other cardiac condition,&#xD;
             hypotension, renal or hepatic disorders, endocrine disorders, prostate or other&#xD;
             cancer, pancreatitis, or a seizure disorder.&#xD;
&#xD;
          8. Subjects with abnormal liver function test (LFTs) as evidenced by laboratory findings&#xD;
             of SGOT or SGPT greater than two times normal.&#xD;
&#xD;
          9. Subjects with a history of adverse reactions to quinazolines or other&#xD;
             alpha-1-antagonists (such as allergic reactions, priapism, hepatitis, angioedema, or&#xD;
             intraoperative floppy iris syndrome).&#xD;
&#xD;
         10. Individuals currently taking alpha blockers (terazosin, prazosin),&#xD;
             hypnotics/benzodiazepines, atypical antipsychotics (olanzapine, quetiapine,&#xD;
             risperidone, clozapine), alpha-2-agonists (Clonidine, methyldopa, tizanidine,&#xD;
             guanfacine), conivaptan, boceprevir, idelalisib, PDE-5 inhibitors or&#xD;
             alpha-1-antagonists, protease inhibitors (treatment of HIV), oral antifungals,&#xD;
             alfuzosin, pazopanib, silodosin, tadalafil, or tamulosin.&#xD;
&#xD;
         11. MRI exclusions: Claustrophobia; tattoos above the shoulders after evaluation by MRI&#xD;
             technician; permanent eyeliner or permanent artificial eyebrows; cardiac pacemaker;&#xD;
             metal fragments in eye, skin, or body, including shrapnel; heart valve replacement;&#xD;
             brain clips; venous umbrella; being a sheet-metal worker or welder; lifetime history&#xD;
             of aneurysm surgery; intracranial bypass, renal, or aortic clips; prosthetic devices&#xD;
             such as middle ear, eye, joint, or penile implants; joint replacements; non-removable&#xD;
             hearing aid, neurostimulator, or insulin pump; shunts/stents; metal mesh/coil&#xD;
             implants; metal plate/pin/screws/wires; or any other metal implants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudie E. Back, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ralph H. Johnson VA Medical Center, Charleston, SC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ralph H. Johnson VA Medical Center, Charleston, SC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401-5799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 7, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <results_first_submitted>March 18, 2021</results_first_submitted>
  <results_first_submitted_qc>March 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 14, 2021</results_first_posted>
  <disposition_first_submitted>January 14, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>January 14, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 19, 2021</disposition_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>alcohol use disorders</keyword>
  <keyword>posttraumatic stress disorder</keyword>
  <keyword>AUD</keyword>
  <keyword>Veteran</keyword>
  <keyword>substance use disorders</keyword>
  <keyword>SUD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxazosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data Sharing Plan: The data collected from study participants, including PHI, will be entered into and securely stored in the STRONG STAR-CAP database on a secure UTHSCSA server by a member of the study research team under a signed Data Use Agreement between Ralph H. Johnson VA and UTHSCSA. Terms of the Data Use Agreement data have been reviewed and approved by VACO and found to meet VA security compliance standards. Electronic data will be stored, managed, and analyzed by the Data Management and Biostatistics Core staff of the STRONG STAR-CAP Consortium. The overall study PI and named collaborators will have access to identifiable data through the STRONG STAR-CAP website and UTHSCSA server.</ipd_description>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02500602/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02500602/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Doxazosin</title>
          <description>Participants randomly assigned to receive doxazosin (target dose of 16 mg/day).&#xD;
doxazosin: active medication</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants randomly assigned to receive Placebo pill&#xD;
placebo: placebo pill</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow Up Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doxazosin</title>
          <description>Participants randomly assigned to receive doxazosin (target dose of 16 mg/day).&#xD;
doxazosin: active medication</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants randomly assigned to receive Placebo pill&#xD;
placebo: placebo pill</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.2" spread="10.9"/>
                    <measurement group_id="B2" value="45.5" spread="11.4"/>
                    <measurement group_id="B3" value="45.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinician Administered PTSD Scale</title>
        <description>The primary PTSD outcome measure was the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5; Weathers et al., 2013). The CAPS-5 is a semi-structured interview that measures the DSM-5 symptoms of PTSD and requires the presence of at least one intrusion symptom, one avoidance symptom, two cognition and mood symptoms, and two arousal symptoms for a period of 1 month or more to reach diagnostic threshold. There are 20 symptom items and responses that are rated on a 5-point scale ranging from 0 (absent) to 4 (extreme/incapacitating), with a total PTSD symptom severity score of the sum of the 20 symptom items ranging from 0-80, and lower scores indicating better outcomes (or less severe PTSD symptomology). The CAPS-5 was assessed at end of treatment (week 12).</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxazosin</title>
            <description>Doxazosin (target dose of 16 mg/day). Doxazosin will be initiated at 1 mg/day for the first week, 2mg/day for the second week, 4mg/day for the third week, 8mg/day for the fourth week, and then increase to 16 mg/day for the remaining eight weeks (as tolerated). R&#xD;
doxazosin: active medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill&#xD;
placebo: placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician Administered PTSD Scale</title>
          <description>The primary PTSD outcome measure was the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5; Weathers et al., 2013). The CAPS-5 is a semi-structured interview that measures the DSM-5 symptoms of PTSD and requires the presence of at least one intrusion symptom, one avoidance symptom, two cognition and mood symptoms, and two arousal symptoms for a period of 1 month or more to reach diagnostic threshold. There are 20 symptom items and responses that are rated on a 5-point scale ranging from 0 (absent) to 4 (extreme/incapacitating), with a total PTSD symptom severity score of the sum of the 20 symptom items ranging from 0-80, and lower scores indicating better outcomes (or less severe PTSD symptomology). The CAPS-5 was assessed at end of treatment (week 12).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" spread="9.6"/>
                    <measurement group_id="O2" value="32.5" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PTSD Checklist (PCL-5)</title>
        <description>The secondary PTSD outcome measure was the PTSD Checklist-5 (PCL-5; Weathers et al., 2013b). The PCL-5 is 20-item self-report measure that assesses the DSM-5 symptoms of PTSD using a severity rating Likert scale ranging from 0 to 4 that indicates the degree of distress across symptoms (0 = not at all to 4 = extremely). The overall score range is 0-80 (and combines the score for all 20 symptoms), with lower scores representing better outcomes (less severe PTSD symptomology). The PCL-5 was assessed at end of treatment (week 12).</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxazosin</title>
            <description>Participants randomly assigned to receive doxazosin (target dose of 16 mg/day).&#xD;
doxazosin: active medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomly assigned to receive Placebo pill&#xD;
placebo: placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Checklist (PCL-5)</title>
          <description>The secondary PTSD outcome measure was the PTSD Checklist-5 (PCL-5; Weathers et al., 2013b). The PCL-5 is 20-item self-report measure that assesses the DSM-5 symptoms of PTSD using a severity rating Likert scale ranging from 0 to 4 that indicates the degree of distress across symptoms (0 = not at all to 4 = extremely). The overall score range is 0-80 (and combines the score for all 20 symptoms), with lower scores representing better outcomes (less severe PTSD symptomology). The PCL-5 was assessed at end of treatment (week 12).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="14.5"/>
                    <measurement group_id="O2" value="46.9" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time Line Follow Back (TLFB)</title>
        <description>The TLFB obtains retrospective self-report of substance use by using a calendar and memory prompts to stimulate recall (Sobell &amp; Sobell, 1992). Quantity and frequency assessments are made using this instrument (e.g., total number of standard drink units, percent of days using) as well as abstinence (yes/no). TLFB yields consistently high test-retest correlations and correlates well with other self-reports and collateral reports (Sobell et al., 2003). The TLFB assesses frequency and amount of substance use over a pre-determined timeframe. TLFB data were collected throughout the trial, and the values reported here represent the TLFB data at end of treatment (week 12).</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxazosin</title>
            <description>Participants randomly assigned to receive doxazosin (target dose of 16 mg/day).&#xD;
doxazosin: active medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomly assigned to receive Placebo pill&#xD;
placebo: placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Time Line Follow Back (TLFB)</title>
          <description>The TLFB obtains retrospective self-report of substance use by using a calendar and memory prompts to stimulate recall (Sobell &amp; Sobell, 1992). Quantity and frequency assessments are made using this instrument (e.g., total number of standard drink units, percent of days using) as well as abstinence (yes/no). TLFB yields consistently high test-retest correlations and correlates well with other self-reports and collateral reports (Sobell et al., 2003). The TLFB assesses frequency and amount of substance use over a pre-determined timeframe. TLFB data were collected throughout the trial, and the values reported here represent the TLFB data at end of treatment (week 12).</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>percentage of days drinking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" spread="34.8"/>
                    <measurement group_id="O2" value="48.1" spread="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percent heavy days drinking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" spread="37.6"/>
                    <measurement group_id="O2" value="38.6" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs collected from baseline (if baseline lasted longer than one appointment) through follow up (12 week treatment phase and 6 week follow up - approximately 20 weeks)</time_frame>
      <desc>Participants were asked about any changes in health or existing symptoms at each visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Doxazosin</title>
          <description>Participants randomly assigned to receive doxazosin (target dose of 16 mg/day). doxazosin: active medication</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants randomly assigned to receive Placebo pill placebo: placebo pill</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>Pt experienced chest pain and was sent to ER by PCP, admitted to hospital for 2 days. Event occurred prior to any medication administration.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Complications</sub_title>
                <description>Dox - Diabetes mellitus with metabolic acidosis Placebo - insulin stopped working</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <description>Internal hemorrhoids</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>Pancreatitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Participant admitted to hospital for dehydration secondary to viral gastroenteritis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <description>Participant fell while running, fractured left shoulder</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation/Attempt</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Anger/Frustration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Homicidal Ideation/Aggression</sub_title>
                <description>Placebo - participant reported feeling extreme anger related to housing. Reported 'intent to harm others' to police in order to be admitted to hospital.&#xD;
Dox-Participant expressed homicidal ideation towards VA security guard and MD</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Substance Use</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Panic Attack/Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Stomach Virus/Cramping/Nausea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="74"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cold/Sinus/Congestion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Generalized Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Accident/Injury</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Joint/Muscle Pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness/Grogginess</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dizziness/Lightheadedness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Sleep Problems</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vivid Dreams/Nightmares</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Emotional Distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sudie Back</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-9383</phone>
      <email>backs@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

